ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03357471
Recruitment Status : Completed
First Posted : November 30, 2017
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

Brief Summary:
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

Condition or disease Intervention/treatment Phase
Moderate and Severe Active Rheumatoid Arthritis Active Psoriatic Arthritis Active Ankylosing Spondylitis Moderately to Severely Active Crohn's Disease Drug: e-Device Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
Actual Study Start Date : November 3, 2017
Actual Primary Completion Date : July 3, 2018
Actual Study Completion Date : July 3, 2018


Arm Intervention/treatment
Experimental: Certolizumab Pegol Q2W injection by e-Device
Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
Drug: e-Device
  • Active Substance: Certolizumab Pegol
  • Pharmaceutical form: Solution for injection
  • Route of administration: subcutaneous injection by e-Device
Other Name: Cimzia

Experimental: Certolizumab Pegol Q4W injection by e-Device
Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
Drug: e-Device
  • Active Substance: Certolizumab Pegol
  • Pharmaceutical form: Solution for injection
  • Route of administration: subcutaneous injection by e-Device
Other Name: Cimzia




Primary Outcome Measures :
  1. Percentage of subjects able to self-administer safe and effective injections using the e-Device at Visit 2 [ Time Frame: Visit 2 (Week 2 for Q2W; Week 4 for Q4W) ]

    Safe and effective self-injection will be evaluated by the healthcare provider and is defined as:

    • Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND
    • No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection

    For subjects on the Q4W (every 4 weeks) dosing regimen who will self-inject twice (2×200 mg CZP) at each visit, each injection will be evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen will be met only if both self-injections are determined to be safe and effective.



Secondary Outcome Measures :
  1. Percentage of subjects able to self-administer safe and effective injections using the e-Device at Visit 1 [ Time Frame: Visit 1 (Week 0) ]

    Safe and effective self-injection will be evaluated by the healthcare provider and is defined as:

    • Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND
    • No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection

    For subjects on the Q4W (every 4 weeks) dosing regimen who will self-inject twice (2×200 mg CZP) at each visit, each injection will be evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen will be met only if both self-injections are determined to be safe and effective.


  2. Percentage of used Certolizumab Pegol (CZP)-cassettes identified as having structural integrity issues based on visual examination [ Time Frame: During the study (from Week 0 up to Week 4) ]
    CZP-cassettes identified as having structural integrity issues means CZP-cassettes with clear evidence of damage/compromised structural integrity, not superficial cosmetic imperfections.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is male or female and must be at least 18 years old at Visit 1
  • Subject must have been diagnosed at least 6 months prior to Visit 1 with documented moderate to severe active Rheumatoid Arthritis (RA), active Psoriatic Arthritis (PsA), active Ankylosing Spondylitis (AS) (in US), or moderately to severely active Crohn's Disease (CD) (in US)
  • A minimum of 10 subjects will have impaired hand function. Impaired hand function will be measured using the Cochin scale (Duruöz et al, 1996; Poiraudeau et al, 2000) and impaired hand function will be defined as patients who have a Cochin score >= 13.5 at Baseline
  • Subjects must have been prescribed Certolizumab Pegol (CZP) and must have been self-injecting CZP using the pre-filled syringe for at least 3 months prior to Visit 1. Subjects with RA, PsA, or AS must have been on a stable Q2W (every 2 weeks) or Q4W (every 4 weeks) CZP dosing regimen for at least 3 months prior to Screening. Subjects with CD must have been on a stable Q4W CZP dosing regimen for at least 3 months prior to Visit 1.
  • Subjects must have been screened according to the applicable national tuberculosis (TB) screening guidelines (to be documented) or provide a documented TB screening activity (TB questionnaire, Interferon-Gamma-Release Assay (IGRA) test, or chest x-ray) within the past 12 months prior to Visit 1.
  • Female subjects of childbearing potential should have a negative pregnancy test at Visit 1 and should be using a medically accepted method of contraception during the entire duration of the study. Female subjects who are postmenopausal for at least 2 years or have undergone a complete hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy, or have a congenital sterility are considered not of childbearing potential

Exclusion Criteria:

  • Subject has participated in another study of an investigational medicinal product (IMP) or an investigational device within the previous 3 months or is currently participating in another study of an IMP or an investigational device
  • Subject has a history of chronic alcohol or drug abuse within the previous 6 months
  • Subject has a history of significant cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, renal, dermatological, neurological, psychiatric, hematological, or bleeding disorders
  • Subjects with known Tuberculosis (TB) infection and at high risk of acquiring TB infection. Subjects with latent TB (LTB) who have not completed the prophylactic treatment regimen for LTB 3 months prior to enrollment
  • Subject has an active chronic/latent infection including but not limited to TB (untreated latent or active), hepatitis virus (HV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
  • Subject has a current malignancy or a history of malignancy. Subjects with less than 3 completely excised basal cell carcinomas or with cervical carcinoma in situ successfully treated surgically more than 5 years prior to Screening may be included
  • Subject has had major surgery (including joint surgery) within 8 weeks prior to Visit 1, or has a scheduled surgery during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03357471


Locations
United States, Arizona
Ra0098 116
Mesa, Arizona, United States, 85202
Ra0098 107
Mesa, Arizona, United States, 85306
Ra0098 135
Phoenix, Arizona, United States, 85037
Ra0098 119
Tucson, Arizona, United States, 85704
United States, California
Ra0098 101
Covina, California, United States, 91722
United States, Florida
Ra0098 131
Clermont, Florida, United States, 34711
Ra0098 132
Coral Springs, Florida, United States, 33071
United States, Georgia
Ra0098 127
Gainesville, Georgia, United States, 30501
United States, Iowa
Ra0098 122
Clive, Iowa, United States, 50265
United States, Missouri
Ra0098 105
Saint Louis, Missouri, United States, 63110
Ra0098 104
Saint Louis, Missouri, United States, 63128
United States, New Jersey
Ra0098 103
Dover, New Jersey, United States, 07801
United States, New York
Ra0098 117
Great Neck, New York, United States, 11021
United States, South Carolina
Ra0098 113
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Ra0098 126
Hixson, Tennessee, United States, 37343
United States, Texas
Ra0098 111
Austin, Texas, United States, 78731
Ra0098 123
Austin, Texas, United States, 78745
Ra0098 102
Austin, Texas, United States, 78758
Ra0098 128
Corpus Christi, Texas, United States, 78404
Ra0098 106
Nassau Bay, Texas, United States, 77058
Ra0098 114
San Antonio, Texas, United States, 78229
United States, Washington
Ra0098 133
Richland, Washington, United States, 99352
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
Study Director: UCB Cares 001 844 599 2273 (UCB)

Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT03357471     History of Changes
Other Study ID Numbers: RA0098
First Posted: November 30, 2017    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
Certolizumab Pegol
E-Device

Additional relevant MeSH terms:
Psoriasis
Certolizumab Pegol
Arthritis
Arthritis, Rheumatoid
Crohn Disease
Spondylitis
Spondylitis, Ankylosing
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Bone Diseases, Infectious
Infection
Bone Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Skin Diseases, Papulosquamous
Skin Diseases
Immunosuppressive Agents
Immunologic Factors